麦全冬定 心先安治疗充血性心力衰竭

Effect of Vedrin Combined with Meglumine Adenosine Cyclophosphate in Treatment of Congestive Heart Failure

目的探讨麦全冬定与心先安联合治疗充血性心力衰竭的临床疗效。方法56例充血性心力衰竭(CHF)患者随机分为对照组和治疗组。对照组常规治疗[吸氧、利尿剂、洋地黄、血管扩张剂、血管紧张素转换酶抑制剂(ACEI)、控制感染和对症支持疗法],治疗组在常规治疗基础上,麦全冬定1.5g加入5%葡萄糖250m l,心先安120mg加入5%葡萄糖250m l静脉点滴,2周为1个疗程,比较两组心功能的改善情况。结果两组治疗后心功能及心脏指数均有显著改善(P<0.01),治疗组与对照组比较差异有统计学意义(P<0.05)。结论麦全冬定与心先安联合应用治疗充血性心力衰竭疗效明显,安全可靠。

Objective To explore clinical effect of Vedrin combined with meglumine adenosine cyclophosphate in patients with congestive heart failure. Methods 56 patients with congestive heart failure were randomly divided into treatment group （ n = 27 ） and control group （ n = 29 ）. The control group was treated with routine therapy including oxygen inhalation, diuretic, digitalis, vasodi- lator, angiotensin - converting enzyme inhibitor（ACEI） , antibiotic therapy, and supporting treatment. The treatment group was treated with Vedrin 1.5g ＋ 5% glucose 250ml intravenously drip, once a day for 2 weeks, meglumine adenosine cyclophosphate 120mg ＋ 5% glucose 250ml intravenously drip, once a day for 2 weeks, as well as routine therapy. After two weeks, the clinical effects compared between two groups. Results The heart function and cardiac indexes were improved after treatment in both two groups（ P 〈0.01 ）, the difference was significant between treatment group and control group after treatment （ P 〈 0. 05 ）. Conclusion Vedrin combined with meglumine adenosine cyclophosphate in treating of congestive heart failure is effective and safe.